매출 하락 → 마진 압박 → 현금 악화
Critical매출이 -18.6% 감소하며 영업이익률이 33.4%에서 33.2%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
매출 YoY -18.6% (2023→2024)영업이익률 33.4%→33.2%영업CF 22→15
Utah Medical Products
UTMD · Nasdaq$71.10+0.55%
2026-09-04 closeUtah Medical Products last closed at $71.10 (+0.55%) on 2026-09-04. Signals today: Death cross, VCP. Listed on Nasdaq; price, financials and dividends update daily after market close.
Loading chart…
Close
데드크로스 · 0d 전
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p
Every new-high-plus-volume pick we actually published (US market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
B+
Overall: 건강관리 298/745 · top 40%
Factor composite · relative position in sector
PER 16.57 · PBR 1.96 — own-history percentile 49/100 · 93/100
Open self-history band
PER49/100
PBR93/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 22 consecutive years · Raised 3 consecutive years · Yield 1.72% (based on 2025 payment of $1.22) · 3-year growth +11.9%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 33.27
Distress
Grey
Safe
- Altman Z''
- 33.27
- Beneish M-Score
- -2.24
- Sloan accrual
- -0.78%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Cash conversion cycleWarning
현금전환주기(CCC) 4기 연속 확대 — 운전자본 경색·현금 회수 지연 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 343 of 543, share 0%.
343 / 5430%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6Utah Medical Products0%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 21
Value lens
- P90/P10
- 24.4
- Median P/B
- 3.02
- Level
- 넓음
- n
- 463
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 33.2%
- Interest coverage
- 48.5x
- Return on equity (ROE)
- 11.8%
Operating margin −5pp
TolerableInterest coverageBase 48.5x adverse case 41.2x
Return on equity (ROE)Base 11.8% adverse case 9.6%
Revenue −15%
TolerableInterest coverageBase 48.5x adverse case 41.3x
Return on equity (ROE)Base 11.8% adverse case 9.6%
Interest rate +2pp
TolerableInterest coverageBase 48.5x adverse case 35.6x
Return on equity (ROE)Base 11.8% adverse case 11.3%
Interest coverage limit
Current margin 32.6ppInterest coverage limit at an operating margin of 0.7%
Interest expense coverage threshold
Connections
AI-extracted related companies · for reference
Customers
Competitors
Becton DickinsonPrice comovement r=0.23 (1 year)ICU MedicalPrice comovement r=0.31 (1 year)Merit Medical SystemsPrice comovement r=0.37 (1 year)TeleflexPrice comovement r=0.28 (1 year)Medline IndustriesAbbott LaboratoriesPrice comovement r=0.19 (1 year)TerumoBaxter InternationalPrice comovement r=0.32 (1 year)
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
About Utah Medical Products
- What technical signals does Utah Medical Products (UTMD) have?
- Utah Medical Products current technical signals: death cross (5_20, 0d ago).
- Is Utah Medical Products a cup-and-handle pattern?
- No. Utah Medical Products has no valid cup-and-handle signal right now.
- What are Utah Medical Products's financials and valuation?
- Utah Medical Products's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy